64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression

NCT04605614 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped slow accruals

Conditions

Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Interventions

RADIATION: Copper Cu 64-DOTA-pembrolizumab
BIOLOGICAL: Pembrolizumab
PROCEDURE: Positron Emission Tomography

Sponsor

City of Hope Medical Center

Collaborators

[object Object]